Transcript Document
Adis R&D Insight™ Vendor Update SLA P&HT Division Meeting April 8, 2008 Adis R&D Insight - Statistics • • • • • • • • • • • Total number of RDI drug profiles = 23,296 Number of new profiles added per month = 80 Number of significant updates per month = 992 Active drug profiles = 43.1% of the total database. Inactive/discontinued drug profiles = 56.9% of database. Number of profiles with chemical structures = 8952 Number of companies covered = 3589 Number of company profiles linked = 406 Number of companies tracked by Lehman Bros = 80-100 Number of profiles with a Lehman table = 995 Therapeutic Area Coverage = ALL plus Diagnostic agents, Cell therapies, Gene therapies and Vaccines. • Number of Indications = 1283 *February 2008 Adis R&D Insight: Sources • Detailed drug profiles derived from the following sources – Company contacts – Press releases – International conferences – Company websites – More than 1,300 biomedical / medical journals Adis R&D Insight NEW! For 2007/2008 • • • • Upgraded search functionality Improved ease of use Links to original sources Major improvements to customizing preferences and push alerting Upgraded Search Functionality Biological and Chemical Class BROWSE function Separate lists for Biological and Chemical classes List View/Tree View option Allows searching on synonyms Upgraded Search Functionality Route and Formulation New tab allows search by • Route of administration • Formulation Upgraded Search Functionality Organization Renamed parameter for better classification of drug developers Search by Organization Type or Ownership Type Upgraded Search Functionality Phase ‘Highest Phase’ and ‘Phase is’ New ‘Phase filter’ option Updated and expanded Phase list Upgraded Search Functionality Country Hierarchy • Country searching is expanded to provide the ability to confidently and simply search by broad geographical / political region. • Addition of ‘Tree View’ Upgraded Search Functionality Fast Track • Allows to search compounds that were assigned Fast Track status by the FDA in the US Upgraded Search Functionality ‘Orphan Drug’ Orphan Drug designation for a particular indication Orphan designation country ‘Any Indication or Country’: search ALL profiles were Orphan Drug exists Upgraded Search Functionality Full Text ‘Full Text’ has replaced the ‘Text Contains’ free text searching option. Can be partnered with a Category, which will search a specific part of the profile. Search term will be highlighted in yellow when you open the profile Improved Ease of Use Addition of Disease Qualifiers a qualifier may be added to an indication a qualifier comment can be added to provide additional information Improved Ease of Use More Tabular Content Route listed in Phase of Development Table Orphan Designation Brand Name Table Links to Original Sources Journal FullText option in records Open access linking capability to link to your journal holdings Customization Results Page Choose Columns for viewing on Results Page Customization Development table Filtering by search Sorting by heading Alerts New ALERTS features: Multiple email addresses can be set up for a single email alert Searches from both R&D Insight and Clinical Trials Insight can be included in a single alert Users will be able to export, print, chart results from their Alerts Run search from last alert Customer Engagement Activities- 2007 • Online Surveys conducted • Key Takeaways – Areas of expanding importance are drug targets and new formulations – Greater need for financial data, patent, and licensing/deals opportunities – Improved ability in accessing specific data points – Timeliness and comprehensiveness is critical Next Steps for Adis R&D Insight • Customer roundtables to determine and continue to drive specific major enhancements – US and Europe during the weeks of March 31st and April 4th – Representation from all user and customer types • Improve comprehensiveness of coverage through the content acquisition initiative (technology and process review) Feedback and Comments Adis Business Intelligence Client Services [email protected] 1-877-872-2347 option 1